clinical trial · NCT05924815
Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval
Cytokinetics·phase1·completed·n = 44
Healthy ParticipantsAficamtenAficamten-matching PlaceboMoxifloxacin
brief summary
This is a single-center, 2-part (Part A and Part B) study in healthy participants. Part A (Dose Finding) is an open-label, SAD study to identify the dose for Part B. Part B (TQT Study) is a randomized, double-blind (with respect to aficamten and matching placebo), positive- and placebo-controlled, single-dose, 3-way crossover study to evaluate the effect of aficamten administration on QT/QTc interval.
started
May 15, 2023
primary completion
Nov 14, 2023
completion
Nov 14, 2023
last updated
Dec 19, 2023
official title
A Randomized, 2-Part, Single-Dose, Crossover Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval in Healthy Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol